Autres langues Exelixis, Inc. Berne S.E.

Actions

EX9

US30161Q1040

Recherche biotechnologique et médicale

Cours en clôture Berne S.E. 29/09/2026			Varia. 5j.	Varia. 1 janv.
48,37 ^CHF	-0,42%		-0,30%	-

15/09	Transcript : Exelixis, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 11:30 AM
11/09	Les ETF et les contrats à terme sur actions en hausse avant l'ouverture vendredi après la publication des données sur l'inflation	MT

Autres langues

11/09	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid Inflation Data Release
11/09	Exelixis, Inc. Extends FDA Review Period for Zanzalintinib New Drug Application in Combination with Atezolizumab for Metastatic Colorectal Cancer
11/09	FDA Extends Review of Exelixis' Zanzalintinib in Colorectal Cancer
11/09	Exelixis Says FDA Extended Review Period for Colorectal Cancer Drug
11/09	US FDA extends review of Exelixis' cancer drug
09/09	Adagene Receives Milestone Payment From Exelixis
01/09	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
31/08	Exelixis Wins Appeal in Patent Case Against MSN Laboratories
31/08	Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
05/08	(EXEL) Exelixis Now Expects Fiscal 2026 Revenue Range $2.50B-$2.55B, vs. FactSet Est of $2.60B
05/08	Earnings Flash (EXEL) Exelixis, Inc. Reports Q2 Revenue $628.7M, vs. FactSet Est of $636.4M
05/08	Earnings Flash (EXEL) Exelixis Posts Q2 Revenue $628.7M, vs. FactSet Est of $636.4M
05/08	Exelixis Q2 Adjusted Earnings, Revenue Rise; Shares Drop After Hours
05/08	Exelixis: Q2 Earnings Snapshot
05/08	Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on May 5, 2026.
05/08	Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on November 4, 2025.
05/08	Exelixis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
05/08	Earnings Flash (EXEL) Exelixis, Inc. Posts Q2 Adjusted EPS $0.91 per Share, vs. FactSet Est of $0.85
05/08	Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
05/08	Exelixis, Inc. Updates Earnings Guidance for Fiscal Year 2026
23/07	Analyst recommendations: Duke Energy, JPMorgan Chase, M&T Bank, Super Micro, Texas Instruments…
22/07	Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
13/07	Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth…
02/07	Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says
02/07	Afternoon Meeting: Wall Street celebra la debilidad